Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer ; volume:15 ; number:1 ; day:28 ; month:2 ; year:2013 ; pages:1-18 ; date:2.2013
Breast cancer research ; 15, Heft 1 (28.2.2013), 1-18, 2.2013
- Urheber
-
Moestue, Siver A.
- Beteiligte Personen und Organisationen
-
Dam, Cornelia G.
Gorad, Saurabh S.
Kristian, Alexandr
Bofin, Anna
Mælandsmo, Gunhild M.
Engebråten, Olav
Gribbestad, Ingrid S.
Bjørkøy, Geir
SpringerLink (Online service)
- DOI
-
10.1186/bcr3391
- URN
-
urn:nbn:de:1111-2016032417075
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Moestue, Siver A.
- Dam, Cornelia G.
- Gorad, Saurabh S.
- Kristian, Alexandr
- Bofin, Anna
- Mælandsmo, Gunhild M.
- Engebråten, Olav
- Gribbestad, Ingrid S.
- Bjørkøy, Geir
- SpringerLink (Online service)
Ähnliche Objekte (12)
Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype
SRC inhibition prevents P-cadherin mediated signaling and function in basal-like breast cancer cells
Inactivation of LATS1/2 drives luminal-basal plasticity to initiate basal-like mammary carcinomas
Weight loss reduces basal-like breast cancer through kinome reprogramming
CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer
Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics
Basal-like breast cancer: molecular profiles, clinical features and survival outcomes
The CD44+/CD24-phenotype is enriched in basal-like breast tumors
Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade
Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment
Gene expression signatures of morphologically normal breast tissue identify basal-like tumors
Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype
SRC inhibition prevents P-cadherin mediated signaling and function in basal-like breast cancer cells
Inactivation of LATS1/2 drives luminal-basal plasticity to initiate basal-like mammary carcinomas
Weight loss reduces basal-like breast cancer through kinome reprogramming
CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer
Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics
Basal-like breast cancer: molecular profiles, clinical features and survival outcomes
The CD44+/CD24-phenotype is enriched in basal-like breast tumors
Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade
Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment
Gene expression signatures of morphologically normal breast tissue identify basal-like tumors
Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype
SRC inhibition prevents P-cadherin mediated signaling and function in basal-like breast cancer cells
Inactivation of LATS1/2 drives luminal-basal plasticity to initiate basal-like mammary carcinomas
Weight loss reduces basal-like breast cancer through kinome reprogramming
CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer
Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics
Basal-like breast cancer: molecular profiles, clinical features and survival outcomes
The CD44+/CD24-phenotype is enriched in basal-like breast tumors
Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade
Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment